Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Trial Phase 1b (Lau et al., 2021) Phase 1b Duration 20 weeks Population (N) Multiple-ascending-dose study Key Result Cagrilintide half-life ~159195 hours
Looking to unlock a reserve of energy you never knew you had
In this article, we will review incretin physiology and evidence supporting a role of GLP-1 in the pathophysiology of hyperinsulinemic hypoglycemia, as well as results from proof-of concept studies exploring a therapeutic approach targeting the GLP-1 receptor to treat hyperinsulinemic hypoglycemia
CDK1 directly binds and phosphorylates the S447 site of ACSL4, promoting the ubiquitination degradation of ACSL4, while genetic and pharmacological blocking of CDK1 enhances ACSL4 activity, promoting ferroptosis of colon cancer cells and increasing their susceptibility to oxaliplatin
US$ 23.45
US$ 29.84
US$ 27.54
US$ 27.02
